Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy

Wang,Jin; Liang,Dong; Zhang,Xue‑Pei; He,Chen‑Fei; Cao,Lei; Zhang,San‑Qi; Xiao,Xue; Li,Shui‑Jie; Cao,Yong‑Xiao

doi:10.3892/ijo.2020.5151

Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy

Authors:
- Jin Wang
- Dong Liang
- Xue‑Pei Zhang
- Chen‑Fei He
- Lei Cao
- San‑Qi Zhang
- Xue Xiao
- Shui‑Jie Li
- Yong‑Xiao Cao
View Affiliations

Affiliations: Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, P.R. China, Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, P.R. China, State Key Laboratory of Bioorganic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, P.R. China, Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 17165 Stockholm, Sweden, Deparment of Pharmaceutical Chemistry, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: November 23, 2020 https://doi.org/10.3892/ijo.2020.5151
Pages: 70-82
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

W922, a novel PI3K/Akt/mTOR pathway inhibitor, exhibits efficient anti‑tumor effects on HCT116, MCF‑7 and A549 human cancer cells compared with other synthesized compounds. The present study aimed to investigate its anti‑tumor effects on colorectal cancer cells. A total, of seven different colorectal cell lines were selected to test the anti‑proliferation profile of W922, and HCT116 was found to be the most sensitive cell line to the drug treatment. W922 inhibited HCT116 cell viability and cell proliferation in vitro in concentration‑ and time‑dependent manners. Furthermore, W922 suppressed the tumor growth in a xenograft mouse model and exhibited low toxicity. The proteomic alterations in W922‑treated HCT116 cells were found to be associated with cell cycle arrest, negative regulation of signal transduction and lysosome‑related processes. W922 caused cell cycle arrest of HCT116 cells in G0‑G1 phase, but only triggered slight apoptosis. In addition, the PI3K/Akt/mTOR signaling proteins were dephosphorylated upon W922 treatment. It has been reported that inhibition of mTOR is relevant to autophagy, and the present results also indicated that W922 was involved in autophagy induction. An autophagy inhibitor, chloroquine, was used to co‑treat HCT116 cells with W922, and it was identified that the cell cycle arrest was impaired. Moreover, co‑treatment of W922 and chloroquine led to a significant population of apoptotic cells, thus providing a promising therapeutic strategy for colorectal cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Brody H: Colorectal cancer. Nature. 521:S12015. View Article : Google Scholar : PubMed/NCBI
3	Stein A, Atanackovic D and Bokemeyer C: Current standards and new trends in the primary treatment of colorectal cancer. Eur J Cancer. 47(Suppl 3): S312–S314. 2011. View Article : Google Scholar : PubMed/NCBI
4	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
5	Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009. View Article : Google Scholar : PubMed/NCBI
6	O'Hara MH, Hamilton SR and O'Dwyer PJ: Molecular triage trials in colorectal cancer. Cancer J. 22:218–222. 2016. View Article : Google Scholar : PubMed/NCBI
7	Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
8	Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, et al: A First-in-human phase 1 study of LY3023414, an oral PI3K/mTOR dual inhibitor, in patients with advanced cancer. Clin Cancer Res. 24:3253–3262. 2018. View Article : Google Scholar : PubMed/NCBI
9	Lech G, Slotwinski R, Slodkowski M and Krasnodebski IW: Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol. 22:1745–1755. 2016. View Article : Google Scholar : PubMed/NCBI
10	Polivka J Jr and Janku F: Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 142:164–175. 2014. View Article : Google Scholar
11	Dienstmann R, Rodon J, Serra V and Tabernero J: Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 13:1021–1031. 2014. View Article : Google Scholar : PubMed/NCBI
12	Hart S, Novotny-Diermayr V, Goh KC, Williams M, Tan YC, Ong LC, Cheong A, Ng BK, Amalini C, Madan B, et al: VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 12:151–161. 2013. View Article : Google Scholar :
13	Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J, Weaver DT, Padval MV, Pachter JA and Xu Q: PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res. 75:446–455. 2015. View Article : Google Scholar
14	Kim YC and Guan KL: mTOR: A pharmacologic target for autophagy regulation. J Clin Invest. 125:25–32. 2015. View Article : Google Scholar : PubMed/NCBI
15	Noda T and Ohsumi Y: Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem. 273:3963–3966. 1998. View Article : Google Scholar : PubMed/NCBI
16	Parzych KR and Klionsky DJ: An overview of autophagy: Morphology, mechanism, and regulation. Antioxid Redox Signal. 20:460–473. 2014. View Article : Google Scholar :
17	Janku F, McConkey DJ, Hong DS and Kurzrock R: Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 8:528–539. 2011. View Article : Google Scholar : PubMed/NCBI
18	Poillet-Perez L and White E: Role of tumor and host autophagy in cancer metabolism. Genes Dev. 33:610–619. 2019. View Article : Google Scholar : PubMed/NCBI
19	Buchser WJ, Laskow TC, Pavlik PJ, Lin HM and Lotze MT: Cell-mediated autophagy promotes cancer cell survival. Cancer Res. 72:2970–2979. 2012. View Article : Google Scholar : PubMed/NCBI
20	Tsujimoto Y and Shimizu S: Another way to die: Autophagic programmed cell death. Cell Death Differ. 12(Suppl 2): S1528–S1534. 2005. View Article : Google Scholar
21	Wang HY, Shen Y, Zhang H, Hei YY, Zhao HY, Xin M, Lu SM and Zhang SQ: Discovery of 2-(aminopyrimidin-5-yl)- 4-(morpholin-4-yl)-6-substituted triazine as PI3K and BRAF dual inhibitor. Future Med Chem. 10:2445–2455. 2018. View Article : Google Scholar : PubMed/NCBI
22	Singla P, Luxami V and Paul K: Triazine as a promising scaffold for its versatile biological behavior. Eur J Med Chem. 102:39–57. 2015. View Article : Google Scholar : PubMed/NCBI
23	McDonald WH and Yates JR III: Shotgun proteomics: Integrating technologies to answer biological questions. Curr Opin Mol Ther. 5:302–309. 2003.PubMed/NCBI
24	Silva MN, Leite JS, Mello MF, Silva KV, Corgozinho KB, de Souza HJ, Cunha SC and Ferreira AM: Histologic evaluation of Ki-67 and cleaved caspase-3 expression in feline mammary carcinoma. J Feline Med Surg. 19:440–445. 2017. View Article : Google Scholar
25	Pandurangan AK: Potential targets for prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev. 14:2201–2205. 2013. View Article : Google Scholar : PubMed/NCBI
26	Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327. 2005. View Article : Google Scholar : PubMed/NCBI
27	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
28	Luo Q and Chen D, Fan X, Fu X, Ma T and Chen D: KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report. Transl Oncol. 13:1008742020. View Article : Google Scholar : PubMed/NCBI
29	Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
30	Liu J, Zhang Y, Qu J, Xu L, Hou K, Zhang J, Qu X and Liu Y: β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer. 11:1832011. View Article : Google Scholar
31	Grana X and Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
32	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
33	Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A and Cascante M: Targeting cell cycle regulation in cancer therapy. Pharmacol Ther. 138:255–271. 2013. View Article : Google Scholar : PubMed/NCBI
34	Zheng K, He Z, Kitazato K and Wang Y: Selective autophagy regulates cell cycle in cancer therapy. Theranostics. 9:104–125. 2019. View Article : Google Scholar : PubMed/NCBI
35	White E: Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 12:401–410. 2012. View Article : Google Scholar : PubMed/NCBI
36	Cook KL, Warri A, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A and Clarke R: Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res. 20:3222–3232. 2014. View Article : Google Scholar : PubMed/NCBI
37	Lee HO, Mustafa A, Hudes GR and Kruger WD: Hydroxychloroquine destabilizes phospho-S6 in human renal carcinoma cells. PLoS One. 10:e1314642015.
38	Neufeld TP: Autophagy and cell growth-the yin and yang of nutrient responses. J Cell Sci. 125:2359–2368. 2012. View Article : Google Scholar : PubMed/NCBI
39	Mathiassen SG, De Zio D and Cecconi F: Autophagy and the cell cycle: A complex landscape. Front Oncol. 7:512017. View Article : Google Scholar : PubMed/NCBI
40	Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016. View Article : Google Scholar : PubMed/NCBI